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Purpose: To investigate if nerve growth factor (NGF) might modulate toll-like receptor (TLR) 4 and 9 expression in
primary cultures of vernal keratoconjunctivitis (VKC)-derived conjunctival epithelial cells (VKC-ECs).
Methods: Primary cultures of ECs were established from VKC (n=7) and healthy-control (n=5) conjunctival specimens.
Primary untouched and short-term NGF-exposed VKC-ECs were analyzed for molecular (relative real-time PCR) and
biochemical (confocal and fluorescence-activated cell sorting analysis of TLR4 and TLR9 expression. Data were compared
to their untreated as well as stimulated healthy-control counterparts. Conditioned media were analyzed for interferon
(IFN)-γ, interleukin (IL)-4, IL-10, and IL-12 p40 secretion.
Results: Primary untouched VKC-ECs showed TLR4 increase and TLR9 decrease compared to their healthy-control
counterparts. NGF exposure resulted in a strong upregulation of TLR4 and a moderate upregulation of TLR9 in few
passages VKC-ECs. Both TLR4 and TLR9 upregulation occurred in a dose-dependent fashion and were supported by
biochemical analysis. NGF triggered a dose-response release of IL-10 in VKC-ECs conditioned media, an effect not
detected for IL-4, IL-12 p40, and IFN-γ.
Conclusions: Our data indicate that NGF is able to induce TLR4/TLR9 overexpression in VKC-ECs. These cells exhibited
poor IL-4, IL-12 p40, and IFN-γ responses to NGF, while a significant IL-10 decreased secretion was detected. The
different NGF-induced TLR response between VKC and healthy-control conjunctival ECs as well as the different cytokine
response might reflect a different pattern of cell activation according to the state of VKC.
Vernal  keratoconjunctivitis  (VKC)  is  a  childhood,
chronic,  allergic  eye  disease,  with  a  multifactorial
pathogenesis [1]. The immune reaction is characterized by T
helper subtype 2 lymphocytes cells, eosinophils, mast cells,
and fibroblast infiltration and/or activation, together with a
complex network of soluble mediators, which can lead to
corneal  complications  [1–3].  Cytokines,  growth  factors,
neuropeptides and other soluble mediators are increased in
tears and active VKC and involve conjunctival epithelial cells
(ECs)  and  fibroblasts  in  the  inflammatory  reaction  [4,5].
Among  these  factors,  nerve  growth  factor  (NGF)  plays
pleiotropic effects on ECs, fibroblast and immune cells [6–
8]. NGF, trkANGFR, and p75NTR are widely expressed in the
healthy  ocular  surface  and  significantly  change  under
pathological states [9–11]. NGF is affected in VKC blood and
tarsal conjunctiva, implying a NGF possibility to modulate
ocular inflammation and epithelial activities [11,12].
Conjunctival ECs play a significant pro-inflammatory
role in VKC by participating in the local immune reaction
throughout  the  synthesis  of  cytokines  known  to  promote
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inflammation  and  expression  of  molecules  (intracellular
adhesion molecule-1) able to recruit inflammatory cells [13].
Being  the  first  line  of  defense,  ECs  express  a  class  of
transmembrane  receptors  named  the  toll-like  receptors
(TLRs)  [13,14].  TLRs  activate  the  innate  (host)  immune
reaction, launch the adaptive immune response, and modulate
the  Th1/Th2  cell  balance  in  several  allergic/autoimmune
disorders [15–17]. In the ocular surface, the widespread TLR
distribution offers a quick and selective response to pathogens
[18,19].  TLR  expression/function  is  highly  dynamic  and
tightly regulated in response to encountered bacterial stimuli
[15]. TLR variation during bacterial/viral infections as well
as  allergic/autoimmune  inflammation  highlights  a  more
complex  functional  mechanism  [18].  We  demonstrated  a
TLR4  transcript  upregulation  and  a  TLR9  transcript
downregulation in VKC-inflamed conjunctival epithelium,
suggesting a TLR contribution in the pathogenesis of the
disease [20].
Some recent findings propose an NGF contribution in the
innate  and  adaptive  immune  responses  [21,22].  Herein,
primary cultures of VKC conjunctival ECs were checked for
TLR4/TLR9 expression and then exposed to exogenous NGF
to  evaluate  TLR4/TLR9  changes  at  either  molecular  and
biochemical  levels  as  well  as  cytokine  release  (interferon
[IFN]-γ,  interleukin  [IL]-4,  IL-10,  and  IL-12  p40)  in  the
conditioned media.
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Tissue sampling and establishment of primary cultures: A
total of 7 patients with active VKC (5 male/2 female, mean
age  15.71±5.59)  and  5  sex/age-matched  healthy-control
patients, who underwent minor surgery, were included in the
study.  Active  VKC  diagnosis  was  based  on  clinical
presentation,  complete  ophthalmic  examination  and  basal
histology (eosinophils in conjunctival scraping). Patients had
recurrent itching, redness, photophobia, tearing in early spring
associated with mild to severe cobblestone-like appearance of
the upper tarsal conjunctiva, mucous discharge, and epithelial
keratopathy. A conjunctival biopsy was obtained from the
upper  tarsal  conjunctiva  of  both  patients  and  controls.  A
signed consent was obtained from each informed participant
(parents/patients). All protocols adhered to the tenets of the
Declaration  of  Helsinki  and  the  ARVO  Statement  in
Ophthalmic  and  Vision  Research  for  research  involving
human  subjects  and  were  performed  according  to  the
Intramural committement. Specimens were cut into several
pieces, put as explants in collagen-coated 24-well plates and
left to attach for 10 min, before adding serum-free media
(dF12  containing  100  U/ml  penicillin  and  100  μg/ml
streptomycin; 37 °C, 5% CO2 in air), to favor the migration of
ECs [23–25]. Cells outgrowing from explants (after 1 week
of culturing) were maintained for an additional 10 days (P0)
and  split/expanded  (P1-2)  according  to  a  standardized
enzymatic-harvest  protocol  (DispaseII  from  ICN,  Milan,
Italy) [25]. Conjunctival ECs were screened for the selective
expression of the defining marker cytokeratin 19 (mouse anti-
human CK19; 1/100, Dako Corp., Carpinteria, CA) and the
absence  of  the  fibroblast  contaminants  Thy-1/α-Smooth
Muscle Actin for Fibroblasts (FB)/myofibroblasts (myoFBs;
Dako).  In  case  of  mycoplasm  contamination  (Hoechst
staining), the cells were one passage-treated with Mycoplasm
Removal  Agent  (5  μg/ml;  ICN).  All  molecular  and
biochemical  reagents  were  purchased  from  ICN,  SERVA
(Weidelberg, Germany), and Euroclone (Milan, Italy), while
sterile tissue culture plasticware were from Nunc (Roskilde,
Denmark).
NGF  dose-response  experiments:  Few  passage  (P1-2)  ECs
were cultured for these studies in order to retain VKC-EC
phenotype. The biological active murine 2.5S βNGF Grade I
(herein referred to as NGF; Alomone Labs. Ltd, Jerusalem,
Israel) was used for the specific dose-response experiments
(1–250 ng/ml). Neutralizing anti-NGF antibodies were from
R&D (Minneapolis, MN). After short-term exposure (24 h),
monolayers were washed in Hanks’ Balanced Sodium Salt
(HBSS)  and  directly  used  for  confocal  analysis  or
enzymatically  harvested  as  single  cells  before  performing
molecular  (relative  real-time  PCR)  or  biochemical
(fluorescence-activated cell sorting [FACS]/ enzyme-linked
immuno-sorbent assay [ELISA]) analysis. Conditioned media
were  assayed  for  cytokine  expression.  Cells  from  each
specimen  were  used  in  independent  experiments  and  not
pooled.
Confocal  analysis:  Monolayers  were  post  fixed  in  4%
buffered-paraformaldehyde (PFA; prepared in 1× phosphate-
buffered  saline  [PBS],  pH  7.5)  and  quenched  in  50  mM
NH4CL  before  fluorescence  staining.  A  brief  blocking/
permeabilizing step (0.8% bovine serum albumin [BSA] and
0.3% Triton-X100 in PBS) was performed before the addition
of the specific antibodies: rabbit anti-human TLR4 (sc-10741;
Santa Cruz Biotech, Santa Cruz, CA), goat anti-human TLR9
(sc-16247; Santa Cruz Biotech), mouse anti-human trkANGFR
and goat anti-human p75NTR antibodies (0.5–1 µg/ml; R&D).
Specie-specific  Cy2/Cy5-conjugated  secondary  antibodies
(Jackson ImmunoResearch Europe Ltd, Suffolk, UK) were
used to detect specific binding. The slides were closed using
an anti-fading medium (Vectamount; Vector Laboratories,
Inc.,  Burlingame,  CA).  Irrelevant  isotype-matched  IgG
antibodies  (Vector  Laboratories,  Inc.)  were  incubated  in
parallel and used as controls for the channel series acquisitions
and related background subtraction. Oil immersion images
were acquired by C1 software connected to an E4000 inverted
microscope (Nikon, Tokyo, Japan). Figures were assembled
in Adobe Photoshop 7.0 (Adobe Systems Inc., San Jose, CA)
and minimal adjustments were made to the figure to obtain
the best quality.
Total RNA extraction, cDNA synthesis and relative real-time
PCR: Total RNA was extracted by OMNIzol (Ambion, Milan,
Italy) and run for real-time RT-PCR amplification (Opticon2
thermocycler; MJ Research, Watertown, MA) with the gene-
specific  primers  for  the  human  TLR4,  TLR9,  trkANGFR,
p75NTR, GAPDH and H3 genes (MWG, Biotech, Ebersberg,
Germany)  [8,20,26].  RNA  was  screened  according  to  the
spectrophotometer  (ND1000;  λ260/280  >1.8;  NanoDrop
Technologies, Wilmington, DE) as well as agarose gel size-
fractionation analysis. cDNA was synthesized from 3 µg total
RNA  using  Moloney  Murine  Leukemia  Virus  (MMLV)
reverse transcriptase (IMPROM; Promega, Milan, Italy). For
amplification,  SYBR  Green  PCR  Master  Mix  (Applied
Biosystems, Foster City, CA) was used, and 47 cycles were
run with denaturation at 94 °C/30 s and extension at 75 °C/30
s with the specific annealing temperatures [8,20,26]. A 60 °C
to 95 °C melting curve was recorded for each sample/gene.
Samples tested negative for DNA contamination, as detected
by amplification of total RNA instead of cDNA. Negative
controls  (without  template)  and  positive  controls  were
produced for each plate run. In pilot experiments, amplicons
were purified (Wizard® SV Gel and PCR Clean-Up System;
Promega) and checked for amplicon identity. Samples were
amplified in triplicate, and from these replicates, averages
were calculated and expressed as real cycle threshold (Ct;
ΔCt = ΔCttarget- ΔCtreference) and reported as normalized ΔCts
±SD or as an expression ratio of a normalized target gene (fold
changes in log2-expression ratio), according to the formula
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software) [27].
FACS analysis: Single cells were processed for membrane/
cytoplasm staining (TLR4/TLR9 diluted 1/100; Santa Cruz),
according to a standardized protocol, including fixation (3.7%
PFA in Hank’s Balanced Salt Solution (HBSS) and blocking/
permeabilization (3% BSA and 0.3% Triton-X100 in HBSS)
treatments.  The  indirect-immunofluorescence  staining  was
carried out with specific primary antibodies followed by FC/
PerCPCy5-coupled, specific, secondary antibodies (Jackson
ImmunoResearch)  in  HBSS  containing  0.3%  Triton-X100
and  0.01%  NaN2.  Control  fluorescent  staining  (isotype-
matched antibodies from eBiosciences, San Diego, CA) was
run  in  parallel  for  each  set  of  experiments.  Cells  were
evaluated by FACSCaliburTM using CellQuestProTM software
(Becton-Dickinson, San Jose, CA). Logarithmic and linear
signals were acquired/analyzed from 5000 gated cells/sample
and presented using WinMDI 2.5 software (the free software
WinMDI, The Scripps Research Institute, La Jolla, CA). A
logical  gate  (back-gating  on  FL3-CK19)  combining
CK19+cells  and  their  scatter  properties  were  used  for
identifying  the  EC  population.  Instrument  setting,
compensation and calibration were performed using 3-color
calibration beads (bdbioscience [BD Biosciences], San Jose,
CA).
Cytokine  secretion  analysis:  Conditioned  media  were
collected and clarified by centrifugation before predilution
and sample loading in 96-well precoated plates. IFN-γ, IL-4,
IL-10,  and  IL-12  p40  levels  were  assayed  using  the
commercially  available  (ELISA)  kits,  according  to  the
manufacturer’s  instructions  (Biosource  International,
Camarillo, CA). Absorbance was detected using an ELISA
reader (Tecan Systems, Inc., San Jose, CA). Normalization
for total protein was achieved between the different treatments
by A280 spectrophotometric analysis (Nanodrop). Cytokine
release is expressed in the text as percentage of release in
comparison to untreated sister cells.
Statistical analysis: Data are expressed as the mean±SD (in
the  text)  or  mean±SEM  (in  figures).  Parametric  ANOVA
coupled with Tukey–Kramer post hoc analysis was used to
detect significant difference (statistical package StatView II
for PC; Abacus Concepts. Inc., San Jose, CA). A p≤0.05 was
considered as statistically significant.
RESULTS
An  increasing  number  of  cuboidal  cells  with  typical
morphology of ECs migrated from the VKC conjunctival
explants by 1 week of culturing (Figure 1A, left) and reached
confluence by 10 days. At confluence outgrew cells were
harvested and analyzed (P0) or replated for dose-response
experiments  (P1–2).  As  detected  by  FACS  analysis,
approximately 97% of gated VKC and healthy-control (P0)
ECs  stained  positive  for  CK19,  a  defining  marker  of
conjunctival ECs (Figure 1A, middle and right). Confocal
analysis on cytospun of untouched primary (P0) VKC-ECs
showed  the  presence  of  TLR4  (Cy2,  middle)  at  either
membrane or cytoplasm points, while TLR9 (cy5, Figure 1A,
right) was mainly localized at the cytoplasm level (Figure 1B,
merge).  Particularly,  a  weak  fluorescence  for  TLR9  was
detected compared to those of TLR4. The in vitro studies were
carried out on primary cultures (P0) and few passages (P1-2)
conjunctival  ECs  in  order  to  retain  the  in  vivo  VKC
phenotype. As previously reported in humans, both trkANGFR
and p75NTR are expressed by VKC epithelium and primary
cultures of ECs [10,12].
Molecular  expression  of  TLR4  and  TLR9  in  VKC
conjunctival  ECs:  Spontaneous  TLR4/TLR9  transcript
expression was evaluated in these untouched primary (P0)
VKC-ECs by relative real-time PCR. Briefly, in VKC-ECs
ΔCt  for  TLR4  was  9.85±5.34  and  ΔCt  for  TLR9  was
16.56±3.78, while in healthy-control ECs, ΔCt for TLR4 was
10.16±2.57 and ΔCt for TLR9 was 5.17±1.12, as detected after
Ct normalization with reference genes (GAPDH and H3). Ct
values  are  inversely  proportional  to  gene  expression.  As
shown in Figure 1C, the REST analysis of the single Ct values
indicate  that  TLR4  transcript  was  increased  while  TLR9
transcript was decreased in primary VKC-ECs compared to
their  healthy-control  counterpart  (+1.23±2.71/-4.03±0.04
TLR4/TLR9,  p<0.01  REST–ANOVA  Tukey–Kramer-
coupled analysis; ranging from -4.15±2.11/-2.37±0.26 TLR4/
TLR9 for mildly active to +1.77±5.90/-6.47±2.81 TLR4/TLR9
for inflamed VKC).
Since NGF ability to modulate TLR4/TLR9 expression
was  hypothesized,  dose-response  studies  were  performed
with exogenous NGF over a 24-h exposure. To perform these
studies, a preliminary check of trkANGFR and p75NTR protein
expression was carried out in passaged VKC-ECs (P1) by
confocal  analysis.  As  depicted  in  Figure  2,  VKC  ECs
expressed both trkANGFR/p75NTR, indicating VKC-ECs as well
as healthy ECs are suitable for in vitro exposure to exogenous
NGF.
Molecular  expression  of  TLR4/TLR9  in  VKC
conjunctival ECs as a function of NGF exposure: In parallel
experiments for few passages VKC and healthy-control ECs,
different TLR4/TLR9 target gene responses were triggered as
a function of short-term NGF. In VKC-ECs, the exposure to
increasing  NGF  doses  resulted  in  a  rising  modulation  of
TLR4/TLR9 expression, with a consistent response for TLR4
(5.40±0.74 at 1 ng/ml, 6.57±0.90 at 10 ng/ml, 9.07±1.17 at
100 ng/ml and 0.26±0.04 at 250 ng/ml NGF; p<0.01 REST–
ANOVA Tukey–Kramer-coupled analysis) with respect to
TLR9 (2.02±0.33 at 1 ng/ml, 3.01±0.55 at 10 ng/ml, 5.55±0.77
at  100  ng/ml,  and  1.23±0.17  at  250  ng/ml  NGF;  p<0.01
REST–ANOVA  Tukey–Kramer-coupled  analysis)  when
compared to untreated VKC-ECs (Figure 3A). This consistent
TLR4/TLR9 transcript upregulation was not monitored when
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presence  of  neutralizing  anti-NGF  antibodies  (0.5  µg/ml;
1.21±0.39 for TLR4 and -1.47±0.08 for TLR9, respectively).
In few passages healthy-control ECs, TLR4 expression was
downregulated (2.97±0.51 at 1 ng/ml, -1.25±0.07 at 10 ng/ml,
-4.18±0.19 at 100 ng/ml, and 0.16±0.05 at 250 ng/ml NGF;
p<0.01  REST–ANOVA  Tukey–Kramer-coupled  analysis),
while TLR9 expression was upregulated (3.27±0.54 at 1 ng/
ml,  1.12±0.24  at  10  ng/ml,  0.85±0.17  at  100  ng/ml,  and
1.67±0.31  at  250  ng/ml  NGF;  p<0.01  REST–ANOVA
Tukey–Kramer-coupled  analysis),  when  compared  to
untreated ones. No significant difference in ΔCt occurred
between primary (P0) and few passages (P1-2) VKC ECs. TLR2
expression was used as an internal control.
Biochemical evaluation of TLR4/TLR9 protein in VKC
conjunctival ECs as a function of NGF exposure: Confocal
analysis revealed that exposure to 100 ng/ml NGF increased
intra-cytoplasm expression of TLR4/TLR9 and led to partial
translocation at the cell surface (Figure 3B). Whole (surface
and  intracellular)  TLR4/TLR9  staining  in  VKC-ECs  was
carried out by FACS analysis to verify whether TLR4/TLR9
transcript  modulation  resulted  in  an  altered  protein
expression.  As  shown  in  Figure  3C,  untreated  VKC-ECs
showed  a  consistent  TLR4  expression  in  comparison  to
undetectable  TLR9  (left),  while  a  consistent  TLR4/TLR9
expression  was  assessed  after  100  ng/ml  NGF  exposure
(right).
Biochemical evaluation of cytokine release from VKC
conjunctival ECs as a function of NGF exposure: Briefly,
IFN-γ,  IL-4,  IL-10  and  IL-12  p40  were  quantified  in
conditioned media from passaged VKC-ECs either untreated
or NGF treated. NGF did not influence IFN-γ, IL-12 p40, or
IL-4 cytokine release in these VKC-ECs. Interestingly, NGF
induced a significant decrease of IL-10 protein release in a
dose-dependent fashion (% decrease: -5.67% at 1 ng/mL,
-39.01% at 10 ng/ml, -59.23% at 100 ng/ml and -59.23% at
250 ng/ml NGF; p<0.01, ANOVA Tukey–Kramer post hoc)
in comparison to untreated VKC-ECs (70.87±4.89 pg/ml).
DISCUSSION
This  study  confirmed  and  extended  in  vitro  the  previous
observation of TLR4/TLR9 expression in VKC conjunctival
epithelium [20]. Short-term NGF exposure triggered a dose-
response  TLR4/TLR9  transcript  upregulation  in  cultured
Figure  1.  Characterization  of  primary
conjunctival  epithelial  cells  outgrew
from  VKC  explants  (VKC-ECs).  A:
Phase contrast microscopy (Normasky)
showing  VKC-ECs  migrating  from
explants after 1 week (left, 10× optic
field). The picture is representative of all
VKC  biopsies.  A  representative
forward/side  scatter  plot  of  gated
primary VKC-ECs (middle) and a FC-
CK19  histogram  demonstrating  the
purity of outgrew ECs (right; solid area:
background staining (negative control);
bold  line:  97%  CK19+  ECs).  B:
Confocal analysis specific for TLR4 and
TLR9 (merge) in VKC-ECs. Control-
isotype signal (data not shown) was used
in  channel  series  acquisitions,  and
identical  acquisition  settings  were
carried  out  for  all  images  (60×  oil
immersion).  C:  TLR4/TLR9  transcript
expression  in  untouched  primary
cultures  of  VKC-ECs  (P0;  p<0.01,
REST-ANOVA  Turkey–Kramer-
coupled analysis).
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analysis. Finally, NGF exposure resulted in a decrease of
IL-10 release without effects on IFN-γ, IL-4 or IL-12 p40, as
detected by the analysis of the conditioned media.
On the ocular surface, NGF (via trkANGFR/p75NTR) exerts
pleiotrophic  effects  and  contributes  to  the  regulation  of
immune response and modulation of the tissue remodeling
that occur in VKC [8–12,28]. Since high trkANGFR expression
was detected in VKC conjunctival epithelium [11] and since
NGF is impaired in VKC conjunctiva [11,12], we wondered
whether exogenous NGF might contribute and/or modulate
TLR4/TLR9  expression  in  VKC  conjunctival  epithelium.
Primary untouched cultures of VKC-ECs showed high TLR4
and low TLR9 expression, in line with those observed in VKC
conjunctival  epithelium  [20]  and  conjunctival  impression
cytologies [unpublished data]. Focused NGF dose-response
studies in few passages VKC-ECs resulted in a steady TLR4
and a moderate TLR9 upregulation at either molecular or
biochemical  levels.  This  NGF-mediated  TLR4/TLR9
upregulation  appeared  strictly  associated  with  VKC
phenotypes, as confirmed by the different NGF effects in
healthy-control counterparts. The lower expressions of TLR4
and  TLR9  at  250  ng/ml  NGF  strengthen  suggest  the
contribution  of  both  trkANGFR/p75NTR  receptors  in  NGF-
mediated TLR4/TLR9 expression, according to kd binding
[9].
The findings of this study suggest an additional NGF
contribution  in  VKC  inflammation.  As  the  ocular  surface
expresses  its  own  (resident)  microflora  and  is  constantly
exposed to foreign substances, TLRs must be highly regulated
to  guarantee  a  quick  response  and  prevent  uncontrolled
inflammatory launch [29,30]. As recently observed, TLRs are
significantly  affected  and  might  contribute  to  the  onset/
ongoing  of  allergic  and  autoimmune  manifestations  [30].
Particularly, several data encompass the role of the Gram-
negative ligand TLR4 in both acute and chronic Th1/Th2
disorders  and  more  interesting  their  contribution  in  the
homeostasis  [14,15,30].  However,  increasing  evidence
supports TLR9-based immunotherapy in allergic disorders, as
shown in the prevention/treatment of experimental models of
allergy  [31,32].  In  previous  studies,  the  NGF/TLR4
association in experimental models and humans as well as the
TLR9/p75NTR  association  in  cultured  fibroblasts  provide  a
possible link between NGF and innate immune response [21,
22]. In this study, NGF-mediated TLR4/TLR9 overexpression
appears extremely attractive since it would imply an increased
EC sensitization to microbial patterns. Alongside pathogens/
commensal bacteria, which represent common TLR activator/
modulator,  other  factors  (growth  factors,  cytokines  and
neuropeptides) might contribute to the cell-surface expression
of  TLRs  [19,33–36].  NGF-mediated  TLR4/TLR9
overexpression might favor a Th1 response according to the
activated cytokine pattern [14,15]. In VKC tears and inflamed
conjunctiva, several cytokines have been detected as a source
of activated ECs [4,5]. Since NGF might be a product and
might  contribute  directly  or  indirectly  to  the  milieu  of
cytokines  (IFN-γ/IL-4/IL-12  p40/IL-10)  detected  in  VKC,
NGF-treated VKC-ECs were also investigated in terms of
cytokine release. As detected in the conditioned media, NGF
did not influence the release of IFN-γ or IL-12 p40, while a
decrease of IL-10 release was detected. This finding implies
that NGF does not modulate Th1/Th2 balance via direct IFN-
γ or IL-12 p40 release. The NGF-mediated IL-10 decrease
might sustain TLR9 overexpression since IL-10 neutralization
significantly  increased  the  deoxycytidylate-phosphate-
deoxyguanylate  (CpG)-induced  IFN-α  response  in  Peyer's
patches [36,37].
An emerging paradigm indicates that commensal bacteria
downregulate  Th2  responses  through  nuclear  factor-κB
activation,  while  reduced  exposure  to  microbial  patterns
Figure 2. TrkANGFR/p75NTR protein expression in primary untouched VKC conjunctival epithelial cells (VKC-ECs). Confocal analysis specific
for trkANGFR (middle) and p75NTR (right) in VKC-ECs. Control-isotype signal (left) was used in channel series acquisitions, and identical
acquisition settings were applied for all images (60× oil immersion).
Molecular Vision 2009; 15:2037-2044 <http://www.molvis.org/molvis/v15/a218> © 2009 Molecular Vision
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Therefore,  a  hypothetical  regulation  of  microflora
composition might offer the possibility to prevent and/or treat
some Th2-linked diseases [18]. The recent observation that a
viral  infection  might  ameliorate  both  clinical  signs  and
symptoms during active VKC as well as the observation that
topical treatment with probiotics resulted in the resolution of
VKC forms [38,39] support this hypothesis. In addition, NGF-
mediated  TLR9  upregulation  might  be  in  line  with  the
observation  that  synthetic  immunostimulatory  sequence
(CpG  motif  ligands)  activates  TLR9,  resulting  in  a  more
effective response than steroids in attenuating both asthma,
allergic conjunctivitis and allergic rhinitis via specific Th2
downregulation [5,39,40]. On the other hand, NGF-mediated
TLR4 expression might suggest an NGF contribution in the
regulation  of  bacterial  clearance,  as  suggested  by  the
observation  that  TLR4  expression  might  drive  a  correct
bacterial clearance in airway cells from children with airway
bacterial colonization [41].
Cytokines,  neuropeptides  and  growth  factors  might
contribute  to  the  modulation  of  TLR  expression  or  be
modulated by TLR-ligand activation. Recent information has
noted  the  role  of  some  soluble  mediators  (histamine),
neurotransmitter  (vasoactive  intestinal  peptide)  or  growth
factors (epidermal growth factor receptor) in the modulation
of  TLR  expression  in  different  cell  types  [14,15,42,43].
According  to  the  NGF  pathway  expression  in  VKC
conjunctiva, exogenous NGF might contribute, either alone
or  in  combination,  to  modulate  innate  response  by
counteracting  TLR9  downregulation  observed  in  VKC
epithelium.  This  NGF-mediated  TLR9  expression  would
allow  a  prompt  response  to  specific  exogenous  and/or
eventual  synthetic  ligands  (probiotics/CpG-DNA).  The
possibility that other inflamed tissue-released factors might
Figure 3. NGF modulates TLR4/TLR9
expression  in  VKC  conjunctival
epithelial cells (VKC-ECs). A: Relative
TLR4/TLR9 transcript expression in few
passages  VKC-ECs  (P1-2).  Short-term
1–250 ng/ml NGF exposure induced a
steady  TLR4  and  a  slight  TLR9
increasing  response  (p<0.01,  REST-
ANOVA  Tukey–Kramer-coupled
analysis).  As  depicted,  the  maximum
effect was observed at 100 ng/ml NGF,
while  its  specific  pretreatment  with
neutralizing anti-NGF antibody resulted
in a downregulation of TLR9 transcripts.
Single  Ct  values  were  normalized  to
referring  genes,  and  folds  were
calculated with respect to their untreated
sister  cells.  B:  Confocal  analysis
specific for TLR4 (middle) and TLR9
(right) in 100 ng/ml NGF-treated VKC-
ECs. Control-isotype signal (left) was
used in channel series acquisitions, and
identical acquisition settings were done
for all images (60× oil immersion). C:
FACS  showed  a  significant
upregulation  of  both  TLR4/TLR9
proteins (5,000 events, right). Note the
absence  of  TLR9  signal  in  untreated
VKC-ECs (left). TLR2 signal was used
as internal control since no difference
was  observed  in  molecular  analysis.
Isotype-matched  control  antibody
staining was in 101 log decade (IF=7.65;
solid  area).  The  graphs  are
representative  of  three  independent
experiments  for  each  sample,  which
gave identical results.
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2042favor  or  counteract  this  NGF-mediated  TLR9  modulation
should be taken into consideration.
Overall, the finding of this study support a theoretical
NGF modulation of immune/adaptive response by means of
TLR4/TLR9  overexpression  in  VKC-ECs.  The  possible
interaction between NGF and TLR4/TLR9 in VKC-ECs could
lead to a new and higher comprehension of VKC pathology
and to the development of nonconventional therapies [31,
44].
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